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Abstract
Background: Type 2 diabetes (T2D) is a strong risk factor for developing neurodegenerative pathologies. T2D
patients have a deficiency in the intestinal incretin hormone GLP-1, which has been shown to exert
neuroprotective and anti-inflammatory properties in the brain.
Methods: Here we investigate potential sources of GLP-1 in the CNS and the effect of diabetic conditions on the
proglucagon mRNA expression in the CNS. The obese mouse model ob/ob, characterized by its high levels of free
fatty acids, and the microglia cell line BV-2 were used as models. mRNA expression and protein secretion were
analyzed by qPCR, immunofluorescence and ELISA.
Results: We show evidence for microglia as a central source of GLP-1 secretion. Furthermore, we observed that
expression and secretion are stimulated by cAMP and dependent on microglial activation state. We also show that
insulin-resistant conditions reduce the central mRNA expression of proglucagon.
Conclusion: The findings that microglial mRNA expression of proglucagon and GLP-1 protein expression are
affected by high levels of free fatty acids and that both mRNA expression levels of proglucagon and secretion levels
of GLP-1 are affected by inflammatory stimuli could be of pathogenic importance for the premature
neurodegeneration and cognitive decline commonly seen in T2D patients, and they may also be harnessed to
advantage in therapeutic efforts to prevent or treat such disorders.
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Background
Type 2 diabetes (T2D) has been identified as a risk fac-
tor for developing neurodegenerative pathologies, such
as Alzheimer’s disease (AD), and stroke [1-3]. Premature
cognitive decline is also a common feature in T2D
patients. Although it has been speculated that chronic
hyperglycemia or recurrent hypoglycemia may be
involved in these derangements, the precise nature of
the underlying mechanisms remain elusive. T2D patients
are not only characterized by hyperglycemia, but typic-
ally also have increased circulating levels of free fatty
acids that may accumulate in the central nervous system
(CNS) [4].
Incretin hormones, such as glucagon-like peptide-1
(GLP-1), are derived from proglucagon, which is pro-
duced by enteroendocrine L-cells, and augment meal-
stimulated insulin secretion in a glucose-dependent
manner [5]. In T2D, the incretin response has been
reported to be impaired as a result of defective GLP-1
secretion [6]. In addition to stimulating insulin secretion,
GLP-1 exerts CNS actions such as neuroprotection and
reduced appetite [7,8] that appear independent of its gly-
cemic effects. Increasing evidence suggests that GLP-1
and its analogs play a very important neuroprotective
role [9]. In GLP-1R knockout mice, neuronal injury is
increased after kainate administration [2,10], and GLP-1
has been shown to protect the neuroblastoma cell line
SH-SY5Y from amyloid-β-induced apoptosis [11]. There
is also evidence that the GLP-1 mimetic exendin-4, clin-
ically used against T2D, improves cognitive perform-
ance [2] and stimulates neurogenesis [12]. In fact, the
National Institute on Aging (NIA) is currently
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recruiting for a clinical trial with exendin-4 for the
treatment of AD. In addition, GLP-1 is well known to
have anti-inflammatory properties in different tissues
[13]. Considering the importance of GLP-1 in both
T2D and neurodegenerative pathologies, and the
strong co-morbidity between T2D and different neuro-
degenerative pathologies, the neuroprotective role and
nature of GLP-1 secretion and action in the brain have
become hot topics. Further, entirely consistent with an
important neuroprotective role of GLP-1, the GLP-1R
is abundantly expressed in many parts of the brain, in-
cluding the hypothalamus, hippocampus and cortex. In
contrast, the only known source of GLP-1 secretion in
the CNS to date is the nucleus tractus solitarius (NTS)
neurons of the brainstem [14], although Iwai et al.
reported the presence of GLP-1 immunoreactive ma-
terial in cultured rat microglia [15]. Here, we aimed to
investigate whether there in fact are non-neuronal
sources of GLP-1 secretion in the brain, and, if so, how
secretion of GLP-1 can be stimulated and how it is
affected by obesity and insulin-resistant conditions.
Such knowledge may shed light on the pathogenesis of
neurodegeneration in T2D patients. Ultimately, this in-
formation may also lead to novel ways of stimulating
neuroprotection in conditions linked to neurodegen-
eration, such as T2D, by modulating the secretion of
one of the brain’s own neuroprotective peptides.
Materials and methods
Animals
Obese (ob/ob) and lean (+/+) male mice were obtained
from our breeding colony of C57BL/6 J-ob/+ mice. The
breeding colony was housed at 23°C, and the mother was
removed from the pups when they were 3 weeks of age.
At 3.5 weeks of age, obese and lean pairs were separated
from their littermates and were housed individually in
solid-bottom, plastic cages with wood shavings and paper
as bedding. The experimental procedures were approved
by Stockholm South local committee on ethics of animal
experiments and performed in accordance with inter-
national standards on animal welfare. All mice had food
and water available ad libitum. At 6-9 months of age, ani-
mals were sacrificed and the brains were removed and
cortex and hippocampus dissected. These brain tissues
were analyzed together. Alternatively, the brains were used
for preparation of tissue sections.
Cell culture and reagents
The BV-2 cell line [16] was cultured in DMEM Glutamax
supplemented with 5% fetal bovine serum, 10,000 U/ml
penicillin and 10 mg/ml streptomycin sulfate under 5%
CO2 at 37°C.
Palmitate (sodium palmitate, Sigma-Aldrich, St. Louis,
MO) exposure medium was supplemented with 0.5%
bovine serum albumin (BSA, fatty acid free; Sigma-
Aldrich). Palmitate was dissolved in 12.5% ethanol
during heating to 60°C. Control cells were given vehicle
with equal amounts of ethanol as the palmitate-exposed
cells. Other reagents used included Forskolin (Sigma-
Aldrich) and lipopolysaccharide (LPS) (Sigma-Aldrich).
Primary rat glial cells cultures consisting of 5-10%
microglia and 90-95% astrocytes were isolated from the
cortex of Sprague-Dawley pups less than 24 h of age as
previously described [17]. Cells were seeded in 60-mm
culture dishes and maintained in DMEM Glutamax con-
taining 10% fetal bovine serum (FBS) and 0.1%
penicillin-streptomycin (PEST) for 20 days (all from
GIBCO). Medium was exchanged every 3-4 day.
Preparation of tissue sections
Isolated mouse brains were placed in 4% paraformalde-
hyde (PFA) (Sigma-Aldrich) and fixated overnight at 4°C.
The fixed tissue was then placed in 30% sucrose and
stored in 30% sucrose at 4°C. Prior to sectioning the tis-
sue, the stage of the cryocutter was cooled by addition of
dry ice. The tissue was mounted on the cold stage using
tissue tech (Histolab, Göteborg, Sweden) and covered in
dry ice long enough to allow the tissue to take a frozen
form. The first few millimeters of tissue was removed, and
then 40-μm-thick coronal sections were cut, using a slid-
ing microtome, throughout the whole brain and placed in
antifreeze prior to storage in -30°C.
Immunohistochemistry/immunocytochemistry
Chromogenic visualization using diaminobenzidine
Tissue sections were washed in phosphate-buffered sa-
line (PBS) 3 × 5 min, quenched in hydrogen peroxide for
15 min, before being washed again in phosphate buffer
containing 0.25% Triton X-100 (PBS-T) 3 × 5 min.
Sections were then incubated overnight at 4°C with the
primary GLP-1-specific antibody (Phoenix peptides) at
1:50 dilution. The primary antibody was detected by use
of biotin-conjugated (Vector) secondary antibody (1:200
dilution). Sections were incubated with the secondary
antibody for 2 h at room temperature (approximately
21°C) in phosphate buffer containing 5% of the appropri-
ate serum and 0.25% Triton X-100. Following this, a 1-h
incubation at room temperature with avidin–biotin com-
plex (ABC kit; Vector) was allowed before subsequent
addition of diaminobenzidine.
Fluorescent visualization
Tissue sections were washed in PBS-T 3 × 5 min,
blocked in 5% milk and incubated overnight at 4°C with
primary antibodies (1:50 dilution in PBS-T containing
5% of the appropriate serum); GLP-1 (Phoenix peptides)
and CD11b (AbDSerotec, Raleigh, NC). Sections were
washed and incubated at room temperature for 1 h in
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the dark with the secondary antibodies (1:1,000 and
1:2,000 dilution in PBS-T), ALEXA Fluor 488 donkey
anti-rabbit and ALEXA Fluor 568 goat anti-mouse (Invi-
trogen). The sections were washed again and mounted on
glass slides using a soft brush to pick them out of the
solution. Sections were allowed to dry in the dark be-
fore mounting the cover slip using mounting medium
(Histolab).
Primary cells were cultured on a cover glass, washed
with pre-warmed PBS-T and fixed with ice-cold 4% PFA
for 10 min at room temperature. Cells were washed with
PBS-T and incubated with primary antibodies (1:50 dilu-
tion in PBS-T containing 5% of the appropriate serum),
GLP-1 (Phoenix peptides) and CD11b (AbDSerotec).
Cells were washed with 5% milk solution and incubated
at room temperature for 1 h (kept dark) with the sec-
ondary antibodies (1:1,000 and 1:2,000 dilution in PBS-T),
ALEXA Fluor 488 donkey anti-rabbit and ALEXA Fluor
568 goat anti-mouse (Invitrogen). The cells were washed
again and incubated for 1 min with DAPI (Invitrogen)
prior to a final wash with PBS. The cover slips with cells
were then mounted upside down on glass slides using
mounting medium (Histolab).
GLP-1 secretion assays
For palmitate treatment, BV-2 cells were plated at a
density of 15,000 cells/cm2 and grown in 24-well plates
for 24 h. Cells were then treated with 0.125 mM palmi-
tate or vehicle for an additional 24 h. Immediately after
the 24 h incubation, medium was collected and DPP-4
inhibitor added (10 μl/ml) (Millipore Corp., Billerica,
MA) to prevent GLP-1 degradation. Samples were stored
at -70°C pending ELISA.
For acute stimulation with agents, BV-2 cells were pla-
ted at a density of 75,000 cells/cm2 and grown in 24-well
plates for 24 h. The medium was discarded, and the cells
were washed with pre-warmed Krebs Ringer buffer
(KRBH) buffer/0.2% BSA/0 mM glucose, followed by a
30-min pre-incubation with the same buffer. Cells were
then treated with LPS (1 μg/ml) or the adenylyl cyclase ac-
tivator forskolin (10 μM) for 2 h. Immediately thereafter,
DPP-4 inhibitor was added (10 μl/ml), and the buffer was
collected. Samples were stored at -70°C pending ELISA.
GLP-1 ELISA (Millipore Corp.) was performed accord-
ing to the manufacturer’s instructions. This ELISA is
specific for the bioactive forms of GLP-1 [GLP-1 (7-36)
amide and GLP-1 (7-37)] and will not detect other forms
of GLP-1. There is no crossreactivity with glucagon. All
experiments were performed in triplicates and repeated
≥ three times to assess consistency of results.
TNFα secretion assay
BV-2 cells were plated at a density of 15,000 cells/cm2
and grown for 24 h prior to exposure to 0.125 mM
palmitate for 24 h or 1 μg/ml LPS for 2 h. The culture
medium was collected and analyzed for TNFα on a solid
phase ELISA kit (R&D Systems, Abingdon, UK) accord-
ing to the manufacturer’s protocol.
RNA extraction, cDNA synthesis and quantitative RT-PCR
BV-2 cells or animal tissue were lysed and RNA
extracted using Aurum total RNA mini kit (catalog no.
7326820; BioRad Laboratories) according to the manu-
facturer’s instructions. cDNA was synthesized for qPCR
using iScript™ cDNA synthesis kit (BioRad Laboratories)
according to the manufacturer’s instructions.
For qPCR, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA expression was used as an internal con-
trol. GAPDH is one of the most commonly used house-
keeping genes for comparisons of gene expression data.
For each sample, the mRNA level of each target gene
relative to GAPDH was estimated by calculating the Del-
taCt or ΔCt (CtTarget Gene − CtGAPDH) and then converting
to 2−ΔCt. To compare mRNA levels between experimental
groups, the ratio of the average 2 −ΔCt for each treatment
group relative to the control group (2−ΔΔCt) was deter-
mined for each gene. This ratio represents a fold change
for each gene. Plotted as arbitrary units are the values gen-
erated for fold change. Differences in the scales/size of ar-
bitrary units between the different analyses (see Figure 2)
stem from the use of samples from different animals in the
different groups skewing the average ΔCt of the groups
and thus the fold change (2−ΔΔCt).
GAPDH primers were designed according to: ATGA
CATCAAGAAGGTGGTG, TGTCATACCAGGAAATG
AGC using Invitrogen custom primer design software
(Invitrogen, Inc.).
Proglucagon primers were designed according to:
GATTTTGTGCAGTGGTTGAT, ACTTCTTCTGGGAA
GTCTTCG using Invitrogen custom primer design soft-
ware (Invitrogen, Inc.).
TNFα primers were designed according to: AAAGT
CAACCTCCTCTCTGC, GGACTCCGCAAAGTCTAAGT
using Invitrogen custom primer design software (Invitrogen,
Inc.).
Interleukin-1β primers were designed according to:
CTTTTCGTGAATGAGCAGAC, GAGGAAAACACAG
GCTCTCT using Invitrogen custom primer design soft-
ware (Invitrogen, Inc.).
Arginase 1 primers were designed according to:
TATGTGTCATTTGGGTGGAT, GCCAATGTACACGA
TGTCTT using Invitrogen custom primer design software
(Invitrogen, Inc.).
Chitinase-3 primers were designed according to: GACT
TGCGTGACTATGAAGC, TGACGGTTCTGAGGAGTA
GA using Invitrogen custom primer design software
(Invitrogen, Inc.).
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A one-step RT-PCR kit with SYBR Green (iScript™
one-step RT-PCR kit with SYBRW Green) (BioRad
Laboratories) was used for real-time quantitative RT-PCR.
This kit utilizes iScript RNase H + reverse transcriptase
and hot-start iTaq DNA polymerase. GAPDH was used as
a housekeeping gene for normalization.
Statistical analysis
Comparisons between control and single treatment
groups with normalized distribution of data were done
using two-tailed Student’s t test. In the case that normal-
ity tests failed, Mann-Whitney rank sum test was used
for comparisons between the control and single treat-
ment group. Correlations were evaluated by determining
the Pearson correlation coefficients. P < 0.05 was
deemed statistically significant.
Results
GLP-1-positive cells are detected in cerebral cortex of mice
and significantly reduced in an obese insulin-resistant
mouse model
To achieve the aim of this study, we investigated
whether GLP-1-positive cells could be detected in parts
of the brain outside of the nucleus of the solitary tract,
where proglucagon mRNA expression has been previ-
ously observed. Results show that GLP-1-positive cells
were indeed detected in cortex and hippocampus of
adult C57 black and ob/ob male mice (Figure 1A). In
addition, the number of GLP-1-positive cells was signifi-
cantly reduced in the obese insulin-resistant ob/ob
mouse model as compared to normal C57 black mice
(Figure 1B).
Proglucagon mRNA expression is detected in cerebral
cortex and hippocampus of mice and significantly
reduced in an obese insulin-resistant mouse model, while
also strongly correlated to the mRNA expression of the
proinflammatory tumor necrosis factor-α (TNFα)
To further confirm our finding of GLP-1-positive cells in an
area outside of the nucleus of the solitary tract, where pro-
glucagon mRNA expression has been previously observed,
we investigated if proglucagon gene expression could be
detected. Results show that proglucagon mRNA expression
was indeed detected in the cortex and hippocampus of adult
C57 black and ob/ob male mice (Figure 2A). In addition, the
expression of the proglucagon gene was significantly
reduced in the obese insulin-resistant ob/ob mouse model
as compared to normal C57 black mice (Figure 2A). Since
low-grade systemic inflammation is recognized in T2D [18],
we also investigated if the expression of the proglucagon
gene was correlated to the presence of inflammation in
these areas of the brain. Thus, we determined the mRNA
expression of the inflammatory markers TNFα and
interleukin-1β (IL-1β) in the same tissue samples. Results
show that, whereas no significant difference in the mRNA
expression of IL-1β (115 ± 15% of expression in C57 black)
could be detected between C57 black and ob/ob mice, sig-
nificantly lower levels of TNFα mRNA expression were
detected in ob/ob mice (Figure 2B). Further, there was a
strong positive correlation between proglucagon mRNA ex-
pression and the mRNA expression of TNFα (Figure 2C).
Microglial cells express the proglucagon gene and secrete
GLP-1 in a cAMP-dependent manner
Since neurons in cerebral cortex and hippocampus have
been reported to lack expression of proglucagon [19],
Figure 1 The number of GLP-1-positive cells in the frontal cortex is reduced in an obese insulin-resistant mouse model. A.
Representative images from the frontal cortex adjacent to the hippocampus of 36-week-old mice showing relative abundance of GLP-1-positive
cells (brown) in C57 black control animals (top left panel) —increased magnification (100 X) of GLP-1-positive cells (top right panel) —as
compared to obese insulin-resistant ob/ob mice (bottom panel). Scale bar: 80 μm. B. Statistical analysis showing a significant decrease in the
number of GLP-1-positive cells/area—in the frontal cortex adjacent to the hippocampus—in obese insulin-resistant ob/ob mice as compared to
healthy controls. Data from 4 C57 black mice and 4 ob/ob mice. Bars represent mean ± SEM. * P < 0.05 for a chance difference vs. C57 black
mice. Statistical analysis was performed using Mann-Whitney rank sum test.
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and after observing the strong correlation of progluca-
gon mRNA expression in these areas to the expression
of the inflammatory marker TNFα, we investigated resi-
dent immune cells of the CNS (microglia) as a possible
source of the proglucagon mRNA expression observed
in these areas of the brain. Co-staining of tissue sections
from the cortex for the CD11b antigen expressed on
monocytes/macrophages and microglia, and GLP-1,
revealed GLP-1-positive microglia in the murine cortex
(Figure 3A). We also investigated GLP-1 expression in
primary rat mixed glial cells and detected GLP-1-
positive microglia cells (Figure 3B). To further confirm
microglia as a source of proglucagon mRNA expression,
as well as regulated GLP-1 secretion, we used the mur-
ine microglia BV-2 cell line. We found that these
microglia-derived cells indeed express the proglucagon
gene and secrete GLP-1 (Figure 3C,D). Previously, cyclic
AMP has been shown to stimulate proglucagon gene
transcription and GLP-1 production in other cell types
[20]. As expected, in microglial cells both mRNA expres-
sion of the proglucagon gene and GLP-1 secretion were
enhanced by adenylyl cyclase activation induced by for-
skolin (Figure 3C,D).
GLP-1 secretion from microglial cells is regulated by
inflammation
In agreement with previous studies [21], classical activa-
tion of BV-2 microglial cells with lipopolysaccharide
(LPS) increases the secretion of TNFα (Figure 4A). We
report here that acute (2 h) activation of BV-2 cells with
LPS also transiently increases proglucagon mRNA ex-
pression, while there is a clear trend toward reduced
proglucagon expression after 24 h (Figure 4B). However,
the increased mRNA expression after 2 h occurs in con-
junction with a significant decrease in the amount of
GLP-1 secreted from these cells (Figure 4C).
Proglucagon mRNA expression is decreased in
alternatively activated microglial cells in an in vitro model
of T2D
Since proglucagon mRNA expression was reduced in the
cortex and hippocampus of ob/ob mice (Figure 1A), we
Proglucagon mRNA expression (A.u.)











































































Figure 2 CNS proglucagon mRNA expression in the frontal cortex is reduced in an obese insulin-resistant mouse model. A. Proglucagon
mRNA expression in obese ob/ob mice as compared to C57 black littermates. Data are from two groups of adult mice, in total 6 C57 black mice
and 9 ob/ob mice, 6-9 months of age. B. TNFα mRNA expression in obese ob/ob mice as compared to C57 black littermates. Data from the same
animals as in A. Proglucagon and TNFα mRNA expression was normalized with mRNA expression of GAPDH, which was used as an internal
control. Bars represent mean ± SEM. *P < 0.05 for a chance difference. Statistical analysis was performed using Mann-Whitney rank sum test.
C. Correlation between proglucagon mRNA and TNFα mRNA. Data from three C57 black mice and five ob/ob mice, 6 months of age; qPCR run in
duplicate at two independent occasions. A.u.; arbitrary units.
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aimed to determine the effects of diabetic conditions on
GLP-1 secretion from microglial cells in vitro. To simu-
late diabetic conditions, we cultured the BV-2 microglial
cells in the presence or absence of a high concentration
(0.125 mM) of the saturated fatty acid palmitate and
determined the amount of GLP-1 secreted into the
medium, as well as proglucagon mRNA expression
levels. Our results demonstrate that high levels of fatty
acid significantly reduced proglucagon mRNA expres-
sion after 2 h, as well as after 24 h. However, no signifi-
cant effect on GLP-1 secretion could be detected in
response to simulated hyperlipidemia (24-h incubation
with palmitate) (Figure 5A,B). Since a strong positive
correlation between proglucagon and TNFα mRNA ex-
pression was detected in vivo (Figure 1C), the effect of
high levels of palmitate on TNFα mRNA expression and
secretion from the microglial cells was determined. In
line with the in vivo results, palmitate significantly
reduced TNFα secretion and mRNA expression after 24 h
(Figure 5C,D). To verify that these effects were not the
result of a toxic effect of palmitate, we measured protein
content in the wells at the end of the 24-h incubation.
Our data demonstrate that palmitate does not alter the
amount of protein in the wells after 24 h (control: 3.90 ±
0.29 μg/μl vs. palmitate: 3.65 ± 0.35 μg/μl). The decrease
in TNFα mRNA expression and secretion in response to
simulated hyperlipidemia (24 h incubation with
palmitate) is unexpected, considering the systemic
inflammation in T2D and that TNFα secretion
increases in response to a classical activation of
microglia cells. This prompted us to investigate a
possible alternative activation of the microglial cells
in response to palmitate. As shown in Figure 5E, we
found that hyperlipidemia simulated by a 24-h
in vitro incubation with 0.125 mM palmitate signifi-
cantly increased the mRNA expression of both chitinase
3-like protein 3 (Ym1) and arginase 1—two markers of al-
ternative activation of immune cells [22], while LPS,
known to induce classical activation of microglia, signifi-
cantly reduced the expression of arginase 1 after 24 h
(Figure 5F). No significant effect on the expression of argi-
nase 1 could be detected after 2 h with LPS/palmitate
(LPS: 103.7 ± 13.7 vs. LPS control: 106.7 ± 28.3/palmitate:
72 ± 11.6 vs. palmitate control 116.9 ± 30.6).
Figure 3 Microglia express proglucagon mRNA and express and secrete GLP-1. GLP-1-positive cells in A, tissue sections from the murine
cortex, and B, primary glial cell cultures, GLP-1-positive (green, top right panel) microglia (red, top left panel). Cells positive for GLP-1 are also
positive for the microglia marker CD11b (bottom left panel), whereas the remaining glial cells in the culture (indicated by blue DAPI staining in
the bottom right panel) are positive for neither GLP-1 nor CD11b. White arrows indicate cells double-positive for CD11b and GLP-1. C. BV-2 cells
secrete GLP-1, and this secretion is stimulated in response to a 2-h treatment with 10 μM of the adenylyl cyclase activator forskolin. GLP-1
secretion was measured as pM and presented as percent of control. D. Expression of proglucagon is increased in response to a 2-h treatment
with 10 μM forskolin. Proglucagon mRNA expression was normalized to mRNA expression of GAPDH, which was used as an internal control. Bars
represent mean ± SEM, n = 3-4, in triplicates. * P < 0.05 for a chance difference vs. untreated controls. Statistical analysis was performed using
Student’s t-test.
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Discussion
Here we show for the first time that BV-2 microglial
cells express the proglucagon gene and secrete GLP-1,
processes that are both enhanced by cAMP. We also
show that this expression of proglucagon is downregu-
lated, in conjunction with a reduced number of GLP-1-
positive cells, in obese insulin-resistant animals in vivo,
an effect mimicked in vitro in a diabetic milieu charac-
terized by high levels of fatty acids. In line with our cen-
tral finding that microglial cells secrete GLP-1, we also
demonstrate that proglucagon mRNA expression and
GLP-1-positive cells are detected in areas of the brain
distinct from the brainstem and the NTS neurons—
where proglucagon expressing neurons have previously
been identified.
Throughout this study we have used ob/ob mice, a
well-known and widely used animal model for obesity
and insulin resistance. The ob/ob mice are characterized
by high levels of free fatty acids and systemic inflamma-
tion [23-25]. The BV-2 cell line is commonly used since
it offers the advantage of being comprised exclusively of
microglial cells and at the same time retains a highly
similar response pattern to primary microglia, especially
in response to inflammatory stimuli [16].
We report here that acute adenylyl cyclase and PKA
activation by forskolin increases proglucagon mRNA ex-
pression and GLP-1 secretion from microglia cells,
showing that the proglucagon and GLP-1 levels can be
manipulated by different stimuli. Further, we report that
classical activation of these cells in vitro, induced by
acute LPS treatment, reduces GLP-1 secretion, while
acutely and transiently increasing proglucagon mRNA
expression, indicating that the acute effect of LPS treat-
ment initially interferes with the secretory mechanism.
The specific steps impaired by LPS will be investigated
in forthcoming studies.
Due to their insulin resistance, T2D patients often
have elevated levels of plasma FFAs [26,27], and recent
studies indicate an increased accumulation of fatty acids
also in the CNS in diabetes [4]. Consequently, we aimed
to evaluate whether high concentrations of fatty acids
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Figure 4 Microglial GLP-1 secretion is decreased in response to inflammatory stimuli. A. TNFα secretion is increased in response to 2-h
and 24-h LPS treatment. TNFα secretion was measured as pg/ml and presented as percent of control. B. Expression of proglucagon is transiently
increased in response to a 2-h treatment with LPS, with a clear trend toward reduced levels after 24 h. Proglucagon mRNA expression was
normalized to mRNA expression of GAPDH, which was used as an internal control. C. Secretion of GLP-1 from BV-2 cells is inhibited by a 2-h
treatment with 1 μg/ml LPS. GLP-1 secretion was measured as pM and presented as percent of control. Bars represent mean ± SEM, n = 3-4, in
triplicates. * P < 0.05 for a chance difference vs. untreated controls. Statistical analysis was performed using Mann-Whitney rank sum test (A,B)
and Student’s t-test (C).
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Figure 5 Proglucagon gene expression in microglia is decreased by the free fatty acid palmitate. Microglia were exposed to 0.125 mM
palmitate for 24 h. A. Proglucagon gene expression is significantly reduced in microglia exposed to palmitate (mimicking the diabetic milieu
in vitro). B. GLP-1 secretion is not significantly reduced after treatment of microglia with palmitate. GLP-1 secretion was measured as pM and
presented as percent of control. C. No significant effect on TNFα secretion is detected after a 2-h exposure to palmitate; however, TNFα secretion
is reduced from microglia treated with palmitate for 24 h. TNFα secretion was measured as pg/ml and presented as percent of control. D. TNFα
expression is significantly reduced in microglia exposed to palmitate. E. Treatment with palmitate increases the expression of chitinase-3 and
arginase 1. F. Treatment with LPS decreases the expression of arginase 1 after 24 h. mRNA expression was calculated after normalizing to mRNA
expression of GAPDH, used as an internal control. Bars represent mean ± SEM, n = 3, in triplicates. * and **P < 0.05 and P < 0.001, respectively, for
chance differences vs. untreated controls. Statistical analysis was performed using Mann-Whitney rank sum test and Student’s t-test (C,D).
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mRNA expression of microglial cells. Palmitate was
chosen to evaluate the effect of high concentrations of
FFAs relevant to T2D, as it is the most studied FFA in
endocrine cell types. We used complexes where the
molar ratio of FFA to albumin was 2:1, which is physio-
logically relevant. We report here that diabetic condi-
tions simulated by palmitate treatment in vitro
significantly reduce proglucagon mRNA expression in
microglial cells.
In support of microglia being a source of the progluca-
gon mRNA expression detected in C57 black mice, the in-
hibitory effect of high levels of palmitate on proglucagon
mRNA expression from microglial cells is in line with the
downregulation of proglucagon gene expression in the ob/
ob mice. However, GLP-1-positive cells are reduced in ob/
ob mice, while GLP-1 secretion is not modified in
palmitate-treated microglial cells. This discrepancy could
stem from the relatively short treatment (24 h) with
palmitate in vitro. It is possible that reduced GLP-1 secre-
tion may come as a consequence of reduced proglucagon
expression and be detectable at a later time point. Another
possibility is that direct effects on GLP-1 secretion by the
relatively short treatment with palmitate in vitro compen-
sates for a reduced number of GLP-1-positive cells in the
culture. Future studies will aim to investigate the rele-
vance of these hypotheses. Noticeably, our results demon-
strate that LPS and 24-h treatment of BV-2 cells with the
saturated fatty acid palmitate will induce opposite effects,
where palmitate treatment will reduce the mRNA expres-
sion and secretion of TNFα, whose induction is character-
istic of a classical activation (LPS activation) of these
immune competent cells, while inducing the alternative
form of microglia activation. Differential activation in re-
sponse to fatty acids and LPS has been reported for
macrophages in other studies [28]. However, there are also
studies supporting an increase in the mRNA expression
and secretion of TNFα from monocytes in response to
palmitate, although these studies generally use much
higher concentrations of palmitate (0.5 mM) [29], which
may not have the same clinical relevance as the concentra-
tion used in this study. Little et al. observed an increase of
IL-8 and MCP-1 in palmitate-treated THP-1 cells [30],
using the same concentration (0.125 mM) of palmitate as
the present study. However, the cell type and the time dif-
fer from this study. Further, it is somewhat inconclusive
what the elevated levels of IL-8 indicate since IL-8 has
been reported to be associated with M2c (a subtype of the
M2 phenotype)-activated macrophages, as reviewed by
David and Kroner [31], as well as with the M1 phenotype.
Moreover, it is well known that the microenvironment
and previous insults to the cells can contribute to the acti-
vation state, thus making it difficult to pinpoint the exact
effect of different stimuli. Further, our in vivo data show-
ing reduced TNFα mRNA expression in an obese insulin-
resistant mouse model further support the fact that high
levels of fatty acids will reduce TNFα mRNA expression
and secretion.
The positive correlation between TNFα and progluca-
gon mRNA expression in C57 black and ob/ob mice
identified in this study, for example, decreased mRNA
expression of an inflammatory cytokine and simultan-
eous decreased mRNA expression of a neuroprotective
peptide, may have its biological importance in protecting
the neurons from cytotoxic factors secreted to kill off in-
vading pathogens. This is of course very speculative, but
the possible biological relevance and importance of these
novel findings should lead to a thorough assessment of
the mechanisms.
The decrease of TNFα in ob/ob mice could stem from a
change in microglia induced by fatty acids toward more
alternatively activated microglia, as indicated by the
present study, and thus lower levels of TNFα. However,
this study does not investigate the effects of simulated
hyperlipidemia in the context of LPS activation of micro-
glia. It is possible, as indicated by studies in other tissues
[32], that, in response to invading pathogens/infections
and release of endotoxins, the high levels of fatty acids
contribute to an enhanced/prolonged immune response
that may have cytotoxic effects. To further investigate pro-
glucagon mRNA expression and GLP-1 secretion in re-
sponse to LPS/amyloid-β under hyperlipidemic conditions
remains part of our future studies. In summary, this study
provides novel information on GLP-1 production in the
brain. We demonstrate that NTS neurons are not the only
central source of GLP-1. Proglucagon is expressed in
other areas of the brain and significantly reduced by (pre)
diabetic conditions in vivo and in vitro. Specifically, this
study demonstrates for the first time that microglia-
derived cells secrete GLP-1 and that this secretion is regu-
lated by the activation state of these cells, by forskolin
leading to PKA stimulation and by LPS. One of our future
research goals, in addition to further characterizing the
mechanisms that regulate GLP-1 secretion from
microglia, is to determine the effects of insulin-resistant
conditions on GLP-1 secretion in vivo by comparing non-
diabetic C57 black and obese ob/ob mice.
The novel information provided in this study and the
central finding that microglia secrete the neuroprotec-
tive peptide GLP-1 may have very interesting pathogenic
and therapeutic implications for the diabetes/neurode-
generative disease interface. Modulating the activation
state of—and the GLP-1 secretion from—microglia
may be a novel option for treating neurodegenerative
diseases.
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